KURA

Kura Oncology Inc

Add to Watchlist

Advanced Chart

5.540

-0.42(-7.047%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

5.860

Open

5.700

VWAP

5.60

Vol

3.43M

Mkt Cap

480.86M

Low

5.470

Amount

19.23M

EV/EBITDA(TTM)

Total Shares

76.18M

-140.25M

EV/OCF(TTM)

-1.12

P/S(TTM)

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a FTI, is being evaluated in a Phase I dose-escalation trial as a monotherapy and in combination with targeted therapies.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

-0.870

+31.82%

-0.249

+13.08%

-0.652

+3.56%

Estimates Revision

The market is revising Upward the revenue expectations for Kura Oncology, Inc. (KURA) for FY2025, with the revenue forecasts being adjusted by 2.15% over the past three months. During the same period, the stock price has changed by -9.03%.

Revenue Estimates for FY2025

Revise Upward

+2.15%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-9.03%

In Past 3 Month

13 Analyst Rating

369.31% Upside

Wall Street analysts forecast KURA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KURA is 26.00 USD with a low forecast of 8.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

11 Buy

2 Hold

0 Sell

Strong Buy

369.31% Upside

Current: 5.540

Low

8.00

Averages

26.00

High

40.00

369.31% Upside

Current: 5.540

Low

8.00

Averages

26.00

High

40.00

Mizuho

Outperform

downgrade

$32 -> $30

2025-05-19

Reason

Mizuho

Price Target

$32 -> $30

2025-05-19

downgrade

Outperform

Reason

Mizuho lowered the firm's price target on Kura Oncology to $30 from $32 and keeps an Outperform rating on the shares. The firm updated the company's model post the Q1 report.

UBS

David Dai

Strong Buy

Maintains

$27 → $14

2025-03-06

Reason

UBS

David Dai

Price Target

$27 → $14

2025-03-06

Maintains

Strong Buy

Reason

UBS lowered the firm's price target on Kura Oncology to $14 from $27 and keeps a Buy rating on the shares. Kura reported Q4 earnings and provided pipeline estimates, and said it recently entered into a licensing agreement with Kyowa Kirin for lead program ziftomenib with 50/50 U.S. sales and 15% royalty on ex-U.S. sales, the analyst tells investors in a research note. Despite recent stock weakness, the firm continues to see zifto as a promising menin inhibitor in Acute Myeloid Leukemia.

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$40

2025-02-27

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$40

2025-02-27

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Maintains

$37 → $40

2025-02-06

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$37 → $40

2025-02-06

Maintains

Strong Buy

Reason

Wedbush

Robert Driscoll

Buy

Maintains

$34 → $36

2025-02-06

Reason

Wedbush

Robert Driscoll

Price Target

$34 → $36

2025-02-06

Maintains

Buy

Reason

Wedbush analyst Robert Driscoll raised the firm's price target on Kura Oncology (KURA) to $36 from $34 and keeps an Outperform rating on the shares. The company announced the KOMET-001 Phase 2 registration-directed study of its menin inhibitor ziftomenib in patients with NPM1-mutated acute myeloid leukemia achieved its primary endpoint and the primary endpoint was statistically significant, the analyst tells investors in a research note. The firm says that while it awaits topline results from KOMET-001, and additional KOMET-007 data in Q2 to further refine its expectations on market positioning versus the competition, it continues to believe ziftomenib holds a potentially best-in-class profile, with Johnson & Johnson's (JNJ) bleximenib likely being the primary competitor. Kura remains undervalued, given the broad potential of ziftomenib in AML, and "patient investors will be rewarded," contends Wedbush.

JMP Securities

Reni Benjamin

Buy

Reiterates

$28

2025-02-06

Reason

JMP Securities

Reni Benjamin

Price Target

$28

2025-02-06

Reiterates

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Kura Oncology Inc (KURA.O) is -2.05, compared to its 5-year average forward P/E of -7.70. For a more detailed relative valuation and DCF analysis to assess Kura Oncology Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-7.70

Current PE

-2.05

Overvalued PE

-3.61

Undervalued PE

-11.79

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.33

Current EV/EBITDA

0.51

Overvalued EV/EBITDA

-0.09

Undervalued EV/EBITDA

-8.56

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

33.51

Current PS

2.44

Overvalued PS

225.31

Undervalued PS

-158.30